- Forschung
- Karriere
- Aktuelles
- Institut
- Durchsuchen
- Spachumstellung
- Leichte Sprache
„”
Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme
The Lancet Neurology 2022
online lesenA high-content neuron imaging assay demonstrates inhibition of prion disease-associated neurotoxicity by an anti-prion protein antibody
Scientific Reports 2022
online lesenPrion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked
Nature Communications 2014
online lesenIn vitro screen of prion disease susceptibility genes using the scrapie cell assay
Human Molecular Genetics 2014
online lesenGlobal microRNA level regulation of EGFR‐driven cell‐cycle protein network in breast cancer
Molecular Systems Biology 2012
online lesenMicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways
Oncogene 2012
online lesenAn identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers
Oncogenesis 2012
online lesenInfrared-based protein detection arrays for quantitative proteomics
PROTEOMICS 2007
online lesenThe full-ORF clone resource of the German cDNA Consortium
BMC Genomics 2007
online lesenHigh-Throughput Flow Cytometry–Based Assay to Identify Apoptosis-Inducing Proteins
SLAS Discovery 2007
online lesenDas Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) gehört zum Forschungsverbund Berlin e.V. (FVB), einem Zusammenschluss von sieben natur-, lebens- und umweltwissenschaftlichen Instituten in Berlin. Die Einrichtungen sind Mitglieder der Leibniz-Gemeinschaft.
Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)
Campus Berlin-Buch
Robert-Roessle-Str. 10
13125 Berlin, Deutschland